Posted by Michael Wonder on 02 Jun 2022
Post-menopausal osteoporosis: advantages of teriparatide over risedronate sodium
2 June 2022 - Preliminary report on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is available. Please submit your comments by 4 July 2022.
In order to answer the question of which of these treatment options for osteoporosis is the best from a post-menopausal woman's point of view, the IQWiG is currently conducting a comparative benefit assessment of bisphosphonates, denosumab and teriparatide on behalf of G-BA.
